Conatus Pharmaceuticals Inc.

Since it has become difficult for many biopharmaceutical companies to raise money during the past year and a half, several firms have been forced to cut costs to make remaining cash balances last long

Zydus Cadila flagship firm Cadila Healthcare Ltd. has received marketing approval from the Drugs Controller General of India for its new chemical entity saroglitazar, to treat non-cirrhotic, non-al

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Strategic Transactions . Histogen’s Regenerative Medi

Neither Novartis AG nor Pfizer Inc. has entered Phase III in non-alcoholic steatohepatitis (NASH) yet, but it seems that the smaller companies ahead in development should be keeping a wary eye on